Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405. https://doi.org/10.1056/NEJMoa1312542.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220–8. https://doi.org/10.1182/blood-2013-11-537167.

Article  CAS  PubMed  Google Scholar 

Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416–30. https://doi.org/10.1056/NEJMoa1716614. Comprehensive genomic characterization for personalized prediction of patients' outcomes and treatment of patients with myeloproliferative neoplasms.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbui T, Carobbio A, De Stefano V. Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pract Thromb Haemost. 2022;6(1):e12657. https://doi.org/10.1002/rth2.12657.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hasselbalch HC, Elvers M, Schafer AI. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood. 2021;137(16):2152–60. https://doi.org/10.1182/blood.2020008109. The inflammatory state created by MPN stem cells amplifies the clinical thrombotic tendency and promote clonal expansion.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Pardanani A. Essential thrombocythemia. N Engl J Med. 2019;381(22):2135–44. https://doi.org/10.1056/NEJMcp1816082.

Article  PubMed  Google Scholar 

Hultcrantz M, Bjorkholm M, Dickman PW, Landgren O, Derolf AR, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168(5):317–25. https://doi.org/10.7326/M17-0028. Patients with MPNs across all age groups have a significantly increased rate of arterial and venous thrombosis compared with matched control.

Article  PubMed  PubMed Central  Google Scholar 

Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–24. https://doi.org/10.1056/NEJMoa035572.

Article  CAS  PubMed  Google Scholar 

Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124(19):3021–3. https://doi.org/10.1182/blood-2014-07-591610.

Article  CAS  PubMed  Google Scholar 

Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32. https://doi.org/10.1200/JCO.2005.07.062.

Article  PubMed  Google Scholar 

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33. https://doi.org/10.1056/NEJMoa1208500.

Article  CAS  PubMed  Google Scholar 

Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–81. https://doi.org/10.1038/leu.2013.163.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857–9. https://doi.org/10.1182/blood-2011-02-339002.

Article  CAS  PubMed  Google Scholar 

Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–33. https://doi.org/10.1182/blood-2012-07-444067. (quiz 252).

Article  CAS  PubMed  Google Scholar 

Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5(11):e369. https://doi.org/10.1038/bcj.2015.94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. https://doi.org/10.1038/s41408-018-0054-y.

Article  PubMed  PubMed Central  Google Scholar 

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–28. https://doi.org/10.1182/blood.2022015850.

Article  CAS  PubMed  Google Scholar 

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179–84. https://doi.org/10.1200/JCO.2010.34.5298.

Article  PubMed  Google Scholar 

Finazzi G, Carobbio A, Guglielmelli P, Cavalloni C, Salmoiraghi S, Vannucchi AM, et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood. 2014;124(16):2611–2. https://doi.org/10.1182/blood-2014-08-596676.

Article  CAS  PubMed  Google Scholar 

Guglielmelli P, Carobbio A, Rumi E, De Stefano V, Mannelli L, Mannelli F, et al. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer J. 2020;10(2):21. https://doi.org/10.1038/s41408-020-0289-2.

Article  PubMed  PubMed Central  Google Scholar 

Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778–82. https://doi.org/10.1182/blood-2009-08-238956.

Article  CAS  PubMed  Google Scholar 

Saliba W, Mishchenko E, Cohen S, Rennert G, Preis M. Association between myelofibrosis and thromboembolism: a population-based retrospective cohort study. J Thromb Haemost. 2020;18(4):916–25. https://doi.org/10.1111/jth.14754.

Article  CAS  PubMed  Google Scholar 

Mora B, Guglielmelli P, Kuykendall A, Rumi E, Maffioli M, Palandri F, et al. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. Leukemia. 2022;36(10):2453–60. https://doi.org/10.1038/s41375-022-01673-3.

Article  CAS  PubMed  Google Scholar 

Barbui T, Ghirardi A, Carobbio A, Masciulli A, Carioli G, Rambaldi A, et al. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score. Blood Cancer J. 2022;12(11):156. https://doi.org/10.1038/s41408-022-00743-0.

Article  PubMed  PubMed Central  Google Scholar 

De Stefano V, Rossi E, Carobbio A, Ghirardi A, Betti S, Finazzi G, et al. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J. 2018;8(11):112. https://doi.org/10.1038/s41408-018-0151-y.

Article  PubMed  PubMed Central  Google Scholar 

Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70. https://doi.org/10.1200/JCO.2010.31.8436.

Article  PubMed  PubMed Central  Google Scholar 

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–69. https://doi.org/10.1038/s41375-018-0077-1. In these guidelines, recommendations on the management of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) by the European LeukemiaNet (ELN) consortium are presented.

Article  PubMed  PubMed Central  Google Scholar 

Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, et al. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(9):1033–62. https://doi.org/10.6004/jnccn.2022.0046. Updated recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia.

Article  CAS  PubMed  Google Scholar 

Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196–208. https://doi.org/10.1016/S2352-3026(19)30236-4. Ropeginterferon alfa-2b offers a valuable and safe long-term treatment option with features distinct from hydroxyurea.

Article  PubMed  Google Scholar 

Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, et al. A randomized phase 3 trial of interferon-alpha vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022;139(19):2931–41. https://doi.org/10.1182/blood.2021012743.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, et al. Benefits and pitfalls of pegylated interferon-alpha2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica. 2018;103(3):438–46. https://doi.org/10.3324/haematol.2017.181297.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013;6(1):49–58. https://doi.org/10.1586/ehm.12.69.

Article  CAS  PubMed